Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Scrip Asks on R&D Innovation; Bayer’s “paradigm-changing” stroke results; AstraZeneca’s precision oncology approach; Gilead’s CMO reflects on pipeline; and India’s pharma chiefs on driving innovation.
Scrip - February 16, 2026

Dexcom Readies For Ireland Plant Coming Onstream In Q4
Dexcom plans to prioritize global expansion in the near future after a few years in which US growth took the company’s focus, CEO Jacob Leach said in a recent earnings call.
Medtech Insight - February 15, 2026

L’Oréal ‘Happy’ To Take Gucci License Early If Possible; Outlines Plans For Scaling Kering Brands
L’Oréal Groupe’s sales for the year advanced 1.3% on a reported basis and 4% like-for-like to €44.05bn, with strong second-half recovery in the US and China. CEO Nicolas Hieronimus projected on growth potential of brands it will obtain through its deal with Kering SA.
HBW Insight - February 15, 2026

Does Organon’s Biosimilars Review Point To Deeper Internal Control Challenges?
Organon’s management declined to discuss the ongoing review, leaving analysts questioning whether the latest issue could signal broader governance or oversight challenges.
Generics Bulletin - February 13, 2026

Teva And GSK Settle Skinny-Label Dispute
Long-running litigation between Teva and GSK over a skinny-label generic carvedilol version of Coreg has ended not with a bang but with a whimper, after the two firms settled on undisclosed terms.
Generics Bulletin - February 13, 2026

Biosimilar Darzalex Progress Caps Busy Few Months For Shanghai Henlius Biotech
Shanghai Henlius Biotech has enjoyed a busy few months advancing multiple biosimilar candidates, including daratumumab, ipilimumab, and nivolumab.
Generics Bulletin - February 13, 2026

Deals Of The Year 2025 Winners Revealed
For In Vivo's 18th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo - February 12, 2026

Podcast: Preventing Lung Disease In Preterm Babies
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
In Vivo - February 12, 2026